House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Rheumatology

Rheumatoid arthritis in adults: management

NICE · 2020 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

NICE rheumatoid arthritis guidance combines early referral for persistent synovitis with prompt DMARD treatment and a treat-to-target strategy. It separates disease control from symptom relief, requires response-based review of advanced therapies and retains multidisciplinary, annual and complication-focused follow-up even when disease activity is low.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Refer persistent synovitis without waiting for reassuring tests

  • Refer unexplained persistent synovitis for specialist assessment. Urgent referral is needed with small-joint hand or foot disease, multiple affected joints or a delay of at least 3 months before seeking advice, even when inflammatory markers or antibodies are negative. [1]
  • In suspected rheumatoid arthritis with clinical synovitis, test rheumatoid factor and consider anti-CCP if rheumatoid factor is negative. Obtain hand and foot radiographs for persistent synovitis, but do not delay referral while investigating. [1]
  • After diagnosis, establish anti-CCP status, baseline erosions and functional ability if not already assessed. Explain that anti-CCP or erosions increase the risk of radiographic progression, and emphasise rapid access if disease worsens. [1]

Set a target and start disease-modifying treatment promptly

  • Treat active rheumatoid arthritis toward remission, or low disease activity if remission is unattainable. Consider remission as the preferred target with baseline anti-CCP or erosions. [1]
  • In specialist care, measure CRP and a composite disease-activity score such as DAS28 monthly during active disease until the treatment target is reached. [1]
  • For adults with newly diagnosed active RA, start conventional DMARD monotherapy as soon as possible, ideally within 3 months of persistent symptoms, using oral methotrexate, leflunomide or sulfasalazine. Escalate as tolerated. Hydroxychloroquine is an alternative to consider for mild or palindromic disease. [1]
  • Consider a short glucocorticoid bridge when starting a new conventional DMARD. If dose escalation does not achieve remission or low activity, add conventional DMARDs in a step-up combination strategy. [1]

Escalate with the appropriate eligibility and response assessment

  • Use the biological and targeted-therapy appraisals according to disease severity, previous adequate conventional treatment and relevant prior biological therapy. Do not treat inclusion in a drug list as eligibility for every patient. [1]
  • Where several treatments are clinically suitable, discuss their benefits and disadvantages before choosing the least expensive overall option under NICE’s cost framework. Include administration and dosing costs. [1]
  • Continue a biological or targeted synthetic DMARD only with at least the specified moderate response at 6 months, and stop if that response is not maintained. Use the relevant appraisal’s response definition. [1]
  • Do not combine a TNF inhibitor with anakinra. Anakinra itself is not recommended for routine RA care outside a controlled long-term study. [1]
  • Use short-term glucocorticoids for rapid relief of a flare. Continue long-term glucocorticoids in established disease only after discussing complications and offering all other options, including biological and targeted therapy. [1]

Address symptoms and function alongside disease control

  • Consider oral NSAIDs when pain or stiffness remains inadequately controlled, after assessing gastrointestinal, hepatic and cardiorenal risk. Use the lowest effective dose briefly, offer a proton pump inhibitor and reassess adverse-event risks. [1]
  • Provide specialist physiotherapy for fitness, flexibility, strength and functional impairment. Provide occupational therapy when daily activities or hand function are difficult. [1]
  • For adults with RA who have pain and dysfunction of the hands or wrists, consider a tailored strengthening and stretching programme if no RA drug regimen is used or the regimen has been stable for at least 3 months. A practitioner with the relevant skills should deliver it. [1]
  • Provide podiatry and indicated insoles or therapeutic footwear for foot problems. Offer psychological approaches to support adaptation, and advise that complementary treatments must not replace conventional therapy. [1]

Maintain surveillance even after reaching target

  • Ensure access to rapid specialist help for flares and ongoing drug monitoring. Consider review 6 months after reaching target to confirm it is sustained. [1]
  • Review every adult annually, including those at target, assessing disease activity, damage, function, comorbidity, possible complications and impact on life. Reconsider the treatment strategy when the target is lost. [1]
  • After at least a year at target without glucocorticoids, consider cautious dose reduction or staged withdrawal. Return promptly to the previous DMARD regimen if control is lost. Do not use ultrasound routinely to monitor disease activity. [1]

Recognise complications requiring prompt specialist intervention

  • Offer an early surgical opinion when optimal nonsurgical treatment does not control pain from damage, worsening function, progressive deformity or persistent local synovitis. [1]
  • Use urgent combined medical and surgical management for suspected or proven septic arthritis, especially in a prosthetic joint. [1]
  • If symptoms suggest cervical myelopathy, such as weakness, paraesthesia or unsteadiness, request urgent MRI and specialist surgical assessment. [1]

Limitations and use

  • This summary does not reproduce the complete biological and targeted-therapy eligibility matrix or drug-specific dosing and safety monitoring.
  • Regulatory and technology-appraisal access details are UK-specific; the summary does not determine current Indian licensing or reimbursement.
  • The relevant adrenal-insufficiency guidance governs glucocorticoid withdrawal; a tapering schedule is not inferred here.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Rheumatoid arthritis in adults: management

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
11 July 2018
Publisher’s latest update
12 October 2020
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Refer persistent synovitis without waiting for reassuring tests
  • Set a target and start disease-modifying treatment promptly
  • Escalate with the appropriate eligibility and response assessment
  • Address symptoms and function alongside disease control
  • Maintain surveillance even after reaching target
  • Recognise complications requiring prompt specialist intervention
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House